PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Cancer
DRUG: PLX2853 20 mg|DRUG: Olaparib|DRUG: Abiraterone acetate|DRUG: Prednisone|DRUG: PLX2853 40 mg|DRUG: PLX2853 80 mg
Number of Participants With Dose-Limiting Toxicities, Dose limiting toxicity defined as clinically significant adverse events or laboratory abnormalities occurring during first cycle of study drug administration that are possibly related to study drug and that meet specific criteria defined in the protocol, From time of first dose of PLX2853 and combination agent(s) through completion of Cycle 1 (21 days)|Phase 1b (Both Arms): Incidence of TEAEs That Are Related to Treatment, Treatment-emergent adverse events are those reported after study drug has been administered., From time of first dose of PLX2853 and combination agent(s) until 30 days from end of treatment (an average of 103 days)|Determination of Maximum Tolerated Dose, To be evaluated in both PLX2853 + AA + pred and PLX2853 + olap group; If DLTs observed in 2 or more subjects the dose will be considered intolerable and MTD will have been reached., From time of first dose of PLX2853 and combination agent(s) through completion of Cycle 1 (21 days)
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)